Q32 Bio Reports Third-Quarter 2026 Results and Clinical Update
Q32 Bio presented additional 36-week results and 16-week off-drug findings from Part B of its SIGNAL-AA trial of bempikibart at the EADV Congress 2026. The company said the data supports further development of bempikibart as a chronic treatment in alopecia areata.
Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking oral and poster presentations at EADV Congress 2026; data supports further development of bempikibart as a chronic treatment in AA ---- Robust durability…